PT  - JOURNAL ARTICLE
AU  - Antoine Joubert
AU  - Fanny Andry
AU  - Antoine Bertolotti
AU  - Frédéric Accot
AU  - Yatrika Koumar
AU  - Florian Legrand
AU  - Patrice Poubeau
AU  - Rodolphe Manaquin
AU  - Patrick Gérardin
AU  - Cécile Levin
TI  - Distinguishing non severe cases of dengue from COVID-19 in the context of co-epidemics: a cohort study in a SARS-CoV-2 testing center on Reunion island
AID  - 10.1101/2020.10.20.20214718
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2020.10.20.20214718
4099  - http://medrxiv.org/content/early/2021/03/06/2020.10.20.20214718.short
4100  - http://medrxiv.org/content/early/2021/03/06/2020.10.20.20214718.full
AB  - Background As coronavirus 2019 (COVID-19) is spreading globally, several countries are handling dengue epidemics. As both infections are deemed to share similarities at presentation, it would be useful to distinguish COVID-19 from dengue in the context of co-epidemics. Hence, we performed a retrospective cohort study to identify predictors of both infections.Methodology/Principal Findings All the subjects suspected of COVID-19 between March 23 and May 10, 2020, were screened for COVID-19 within the testing center of the University hospital of Saint-Pierre, Reunion island. The screening consisted in a questionnaire surveyed in face-to-face, a nasopharyngeal swab specimen for the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) reverse transcription polymerase chain-reaction and a rapid diagnostic orientation test for dengue. Factors independently associated with COVID-19 or with dengue were sought using multinomial logistic regression models, taking other febrile illnesses (OFIs) as controls. Adjusted Odds ratios (OR) and 95% Confidence Intervals (95%CI) were assessed. Over a two-month study period, we diagnosed 80 COVID-19, 60 non-severe dengue and 872 OFIs cases. Among these, we identified delayed presentation (>3 days) since symptom onset (Odds ratio 1.91, 95% confidence interval 1.07-3.39), contact with a COVID-19 positive case (OR 3.81, 95%CI 2.21-6.55) and anosmia (OR 7.80, 95%CI 4.20-14.49) as independent predictors of COVID-19, body ache (OR 6.17, 95%CI 2.69-14.14), headache (OR 5.03, 95%CI 1.88-13.44) and retro-orbital pain (OR 5.55, 95%CI 2.51-12.28) as independent predictors of dengue, while smoking was less likely observed with COVID-19 (OR 0.27, 95%CI 0.09-0.79) and upper respiratory tract infection symptoms were associated with OFIs.Conclusions/Significance Although prone to potential biases, these data suggest that non-severe dengue may be more symptomatic than COVID-19 in a co-epidemic setting with higher dengue attack rates. At clinical presentation, eight basic clinical and epidemiological indicators may help to distinguish COVID-19 or dengue from each other and other febrile illnesses.Author Summary As coronavirus 2019 (COVID-19) is spreading globally, several countries are facing dengue epidemics with the fear the two plagues might overburden their healthcare systems. On Reunion island, southwestern Indian ocean: dengue virus is circulating since 2004 under an endemo-epidemic pattern with yearly outbreaks peaking between March and May since 2015, whereas Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), the pathogen responsible of COVID-19, emerged in March 2020, imported from the Bahamas. COVID-19 and dengue are deemed two clinically similar entities, especially within the first two days from symptom onset. In this context, we conducted a cohort study between March 23 and May 10, 2020, within a SARS-CoV-2 testing center, aimed at identifying the factors discriminating both infections. Surprisingly, we found that non-severe dengue was more symptomatic than mild to moderate COVID-19. Indeed, we found body ache, headache and retro-orbital pain to be indicative of dengue, whereas contact with a COVID-19 positive case, anosmia, delayed presentation (>3 days post symptom onset) and absence of active smoking were indicative of COVID-19. These findings highlight the need for accurate diagnostic tools and not to jeopardize dengue control in areas wherever COVID-19 dengue co-epidemics have the potential to wrought havoc to the healthcare system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding for this study conducted within standard care proceduresAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Outpatients presenting consecutively at the SARS-CoV-2 testing center were informed of the study orally and by means of an information sheet. Adult people, like the children under 18 years (with the additional verbal consent of their parent or legal guardian) who expressed no opposition, were asked to answer a questionnaire and surveyed in face-to-face by a nurse, in accordance to the French legislation on bioethics for retrospective researches. Patient medical records were retrospectively reviewed, and de-identified data were collected in standardized forms according to the MR-004 procedure of the Commission Nationale Informatique et Libertes (the French information protection commission). The ethical character of this study on previously collected data was approved by the Scientific Committee for COVID-19 research of the CHU Reunion and de-identified data were registered on the Health Data Hub.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be processed for the development of a scoring system. After having submitted our second paper, we will provide an access to the data in a data repository according to data sharing. In the meantime, data availability will be discussed on requestCIRcumulative incidence rate (= attack rate)CNRcentre national de referenceCOVID-19coronavirus disease of 2019DENVdengue virusOFIsother febrile illnessesaORadjusted odds ratioRT-PCRreverse transcription – polymerase chain reactionSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SpO2Saturation of peripheral oxygenUDACSunite de dépistage ambulatoire du coronavirus sudURTIupper respiratory tract infection95% CI95% confidence intervals